BC Centre for Excellence in HIV/AIDS lauds US Health Organization

December 02, 2009

Vancouver, British Columbia, Canada, December 2, 2009 - Dr. Julio Montaner - Director, British Columbia Centre for Excellence in HIV/AIDS (BC-CfE), and President, International AIDS Society - congratulated Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH), for taking a leadership role in the evaluation of the "Seek and Treat" strategy originally developed at the BC-CfE.

NIH has issued a Request for Applications (RFA) that will invest up to $50 million over five years to evaluate "seek and treat" in the criminal justice setting. NIDA's funding, along with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH), will foster the development, implementation and testing of strategies to seek, test, and treat HIV-infected people within the criminal justice system. The RFA is open to applicants from outside the U.S. "Several mathematical models suggest that increasing access to HIV testing and treatment, particularly among high risk groups, could have a substantial beneficial impact - not only on individuals' health, but also on population infection rates," says NIDA Director Dr. Nora Volkow. "That's why we're investing substantial resources to determine the real-world impact of a 'seek, test, and treat' approach, because so many HIV-infected people pass through the criminal justice system every year."

The research will be closely focused on the continuity of highly active antiretroviral therapy (HAART) during and after community re-entry following periods of incarceration. This strategy is expected to decrease HIV/AIDS related morbidity and mortality among inmates and decrease HIV transmission among their network members. "Research conducted in BC over the last five years shows that we must seek out and offer treatment to all medically eligible HIV-infected individuals to stop the progression to AIDS and death among those infected and prevent HIV infection among those at risk. Lessons learned from this research will be essential to guide further roll out of the treatment globally," said Montaner.

The "seek and treat" strategy is particularly intended to dramatically increase access to the life-saving HAART treatment among vulnerable people such as injection-drug users, sex-trade workers, prisoners, First Nations individuals, and those with other underlying conditions such as mental illness. All of these populations are overrepresented in the correctional system. "Reaching out to these populations to provide rapid HIV testing and access to appropriate therapy will save lives and avert infections, making this a cost-averting proposition," said Montaner.

On September 5, 2008, NIDA announced that Dr. Montaner was a recipient of the inaugural Avant-Garde Award of US $2.5 million over five years to support the BC-CfE's project, Seek and Treat to Optimize Prevention of HIV & AIDS (STOP HIV/AIDS).

"NIDA's leadership in funding our proposed 'seek and treat' strategy is extremely exciting news in the fight against HIV/AIDS, both in the United States and around the world," said Montaner.

Since then, the BC-CfE has published new evidence that shows that decreasing plasma HIV-viral load in the community with expanded HAART coverage among injection drug users dramatically decreases AIDS-related morbidity and mortality (Wood et al, JAMA 2008;300:550) and new HIV infections (Wood et al, BMJ 2009;338:b1649).

"It's a significant achievement that 'seek and treat' is now accepted by the global medical community as a key pillar to fight HIV/AIDS," said Dianne Doyle, President and CEO, Providence Health Care. "Providence is greatly encouraged that NIDA, a leading international health research organization, is providing significant funding to further study ways to optimally integrate the strategy of our BC Centre for Excellence in HIV/AIDS in specific settings. This clearly demonstrates the importance of working collaboratively to advance the best possible strategies to control the spread of HIV/AIDS globally."

"The research undertaken by NIDA and the BC-CfE is critical to understanding where we should best put our resources to prevent unnecessary AIDS mortality and HIV infections," said Professor Stephen Toope, President, University of British Columbia (UBC). "As the host of the G8/G20 meeting in 2010, Canada has an opportunity and a responsibility to build on these results for the benefit of the international community. We are proud of the progress that UBC-based investigators have made as we strive to eliminate HIV and other emerging diseases."
About the B.C. Centre for Excellence in HIV/AIDS:

The BC Centre for Excellence in HIV/AIDS (BC-CfE) is Canada's largest HIV/AIDS research, treatment and education facility. The BC-CfE is based at St Paul's Hospital, Providence Health Care, and a teaching hospital of the University of British Columbia. Located in Vancouver, Canada, the BC-CfE is dedicated to improving the health of British Columbians with HIV through the development, monitoring and dissemination of comprehensive research and treatment programs for HIV and related diseases.

About Providence Health Care:

Providence Health Care (PHC) is one of Canada's largest faith-based health care organizations, operating 14 health care facilities in Greater Vancouver. A renowned academic health science leader, PHC focuses its services on six "populations of emphasis": cardio-pulmonary risks and illnesses, HIV/AIDS, mental health, renal risks and illness, specialized needs in aging and urban health.

About the University of British Columbia:

The University of British Columbia (UBC) is one of Canada's largest and most prestigious public research and teaching institutions. It is consistently ranked among the world's 40 best universities. UBC attracts more than $450 million per year in research funding and is ranked within the top 10 in North America, and first among Canadian universities, in the number of U.S. life-sciences patents and the quality of activity generated from those patents, including spin-off company creation.

University of British Columbia

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.